ʻIke Hou e pili ana i ka Warm Antibody Autoimmune Hemolytic Anemia

A HOLD Hoʻokuʻu ʻole 4 | eTurboNews | eTN
Avatar o Linda Hohnholz
i kakauia ma Linda Hohnholz

ʻO Rigel Pharmaceuticals, Inc. i kēia lā hoʻolaha i ka hoʻolaha ʻana o ka ʻikepili i ka American Journal of Hematology mai ka lepili hāmama, multicenter, Phase 2 clinical study of fostamatinib i nā pākeke me ka pumehana antibody autoimmune hemolytic anemia (wAIHA) i hāʻule ma ka liʻiliʻi o hoʻokahi lapaʻau mua. Hōʻike ka ʻikepili i paʻi ʻia ʻo ka fostamatinib, he mea hoʻopuʻi waha spleen tyrosine kinase (SYK), hoʻonui wikiwiki a lōʻihi hoʻi ka hemoglobin (Hgb), me nā pane Hgb koʻikoʻi i ʻike ʻia ma kahi kokoke i ka hapalua o nā maʻi, a me kahi hōʻike palekana a me ka hoʻomanawanui e kūlike me ka mea e kū nei. fostamatinib palekana waihona o nā maʻi ma nā papahana maʻi he nui i aʻo ʻia. ʻO ka hoʻolaha, i kapa ʻia ʻo "Fostamatinib no ka mālama ʻana i ka antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study", aia ma ka pūnaewele puke pai.

"ʻO nā hopena i ʻike ʻia i kā mākou haʻawina Phase 2 i ka anemia hemolytic autoimmune wela e hoʻoikaika i ka hiki o ka fostamatinib e kōkua i nā poʻe maʻi me kēia maʻi koko koʻikoʻi a ʻaʻole i ʻae ʻia nā lāʻau lapaʻau i kēia manawa," wahi a Raul Rodriguez, ka pelekikena a me ka luna nui o Rigel. luna. "Inā ʻae ʻia, hiki i ka fostamatinib ke lilo i ka lāʻau lapaʻau mua i ka mākeke no nā poʻe maʻi me wAIHA i 2023 a ʻo ia ka hōʻailona ʻelua o ka fostamatinib."

Ua loiloi ka haʻawina ʻo Phase 2 i ka pane ʻana i ka fostamatinib ma 150 mg BID (ʻelua ʻelua i kēlā me kēia lā) i nā poʻe maʻi makua me ka wAIHA a me ka hemolysis ikaika me ka Hgb o lalo o 10 g/dL i hāʻule ʻole ma kahi o hoʻokahi lapaʻau mua. ʻO ka hopena mua ʻo Hgb ʻoi aku ka nui ma mua o 10 g / dL me ka piʻi ʻana o ≥2 g / dL mai ka papa kuhikuhi ma ka Week 24 me ka hoʻopakele ʻana a i ʻole ka lawe ʻana i ke koko ʻulaʻula. Ua hōʻike ka haʻawina i ka 46% (11/24) o nā maʻi i hoʻokō i ka hopena mua, me ka 1 hope pane i ka pule 30 (ka huina o 12 pane [50%]). Ua ʻike ʻia ka piʻi ʻana o ka Hgb median ma ka pule 2 a mālama ʻia i ka manawa. ʻO nā hopena ʻino loa (AE) ʻo ia ka maʻi maʻi (42%), ka luhi (42%), ke koko kiʻekiʻe (27%), ka noʻonoʻo (27%), a me ka insomnia (23%). Hiki ke hoʻokele a kūlike nā AE me ka waihona palekana fostamatinib o nā mea maʻi he 3,900 ma waena o nā maʻi he nui (rheumatoid arthritis, B-cell lymphoma, COVID-19, a me immune thrombocytopenia (ITP)). ʻAʻole i ʻike ʻia nā hōʻailona palekana hou.

No ka mea kākau

Avatar o Linda Hohnholz

Linda Hohnholz

Lunahooponopono no eTurboNews ma ka eTN HQ.

kakau
E hoʻomaopopo i
malihini
0 Comments
Nā ʻōlelo Hoʻohui Kūʻai
E nānā i nā ʻōlelo āpau
0
E aloha nui i kou mau manaʻo, e ʻoluʻolu.x
()
x
Kaʻana like i...